Tempest Therapeutics, Inc. (TPST) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 3, 2026, details the completion of a strategic asset acquisition and significant corporate governance changes for Tempest Therapeutics, Inc. The filing reports on events occurring on February 3, 2026, including the closing of an Asset Purchase Agreement originally executed on November 19, 2025, and the subsequent issuance of equity and warrants.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins, as this is a current report regarding specific corporate events rather than a periodic financial statement.
- Asset Acquisition Consideration: The Company issued 8,268,495 shares of Common Stock to Erigen LLC (on behalf of Sellers) in exchange for four CAR T-cell therapy assets (ERI-2003, ERI-2206, ERI-3003, and ERI-3206).
- Warrant Distribution: The Company issued 6,784,989 Warrants as a dividend to shareholders of record on January 30, 2026. Each Warrant allows the purchase of one share of Common Stock at an exercise price of $18.48, expiring on February 3, 2031.
- Outstanding Shares: Immediately following the share issuance, there were 13,481,070 shares of Common Stock outstanding.
- Executive Compensation: New CEO Matthew Angel, Ph.D., received an annual base salary of $650,000, a target annual bonus of 50% of base salary, and an option to purchase 269,621 shares of Common Stock.
Material Changes Versus Prior Period
The most significant material change is the shift in control and ownership structure resulting from the asset acquisition.
- Change in Control: Following the issuance of shares to Erigen, pre-closing equityholders owned approximately 38.7% of the outstanding shares, while Erigen owned approximately 61.3%. After distribution to Erigen's members and pre-closing equityholders, Erigen's members are expected to own approximately 35.9% and pre-closing equityholders approximately 25.5%.
- Leadership Transition: Stephen Brady resigned as President, CEO, and Board Chair. Matthew Angel, Ph.D., was appointed President, CEO, and a Class I Director. Michael Raab stepped down as Chair, succeeded by Stephen Brady.
- Board Composition: Geoff Nichol resigned from the Board effective immediately.
Outlook, Risks, and Unusual Items
Strategic Outlook: The acquisition of the four CAR T-cell therapy assets (two autologous and two allogeneic) marks a pivot in the Company's pipeline, focusing on BCMA/CD19 and CD70/CD70 dual-targeting therapies.
Risks and Contingencies:
- Registration Requirement: The Warrants issued cannot be exercised until an effective registration statement covering the sale of shares upon exercise is filed. The Company intends to file this statement under the Securities Act of 1933.
- Unregistered Securities: The Warrants and the shares issued to Erigen were not registered under the Securities Act, relying on exemptions under Section 2(a)(3), Section 3(a)(9), and Section 4(a)(2).
- Executive Retention: The new CEO's employment is at-will. Severance provisions include 12 months of base salary and 100% of the target bonus for termination without Cause, increasing to 18 months and 150% of the target bonus in the event of a Change in Control.
Key Facts for Investor Verification
- Verify the effective date of the registration statement for the 6,784,989 shares issuable upon exercise of the Warrants to confirm when they become exercisable.
- Confirm the final ownership percentages of Erigen's members and pre-closing equityholders following the distribution of shares.
- Review the full text of the Asset Purchase Agreement (Exhibit 10.1 to the November 19, 2025, 8-K) for details on the specific assets acquired and any contingent liabilities.
- Monitor the Company's cash position and burn rate, as the filing does not disclose current liquidity levels or the impact of the new executive compensation package on future cash flow.